(Q48062723)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Chul Won Jung

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Lee-Yung Shih

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Zhijian Xiao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Jin Jie

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Hsin-An Hou

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Xin Du

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ming-Chung Wang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Seonyang Park

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ki-Seong Eom

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Kenji Oritani

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Shinichiro Okamoto

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Tetsuzo Tauchi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Daobin Zhou

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Shigeki Saito

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Junmin Li

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Hiroshi Handa

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Li Jianyong

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Kohshi Ohishi

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ming Hou

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Wu Depei

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Katsuto Takenaka

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ting Liu

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Yu Hu

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Taro Amagasaki

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Kazuo Ito

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Prashanth Gopalakrishna

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Koichi Akashi

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

20 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

2067-2074

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315076%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic approaches in myelofibrosis.

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

MPN-associated myelofibrosis (MPN-MF).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

Risk factors for leukemic transformation in patients with primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260

Primary myelofibrosis: update on definition, pathogenesis, and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.969260